

FUSIONPlex[®]




RNA-BASED FUSION, EXPRESSION
AND VARIANT DETECTION

Comprehensive coverage of recurrent, rare and novel fusions




NOVEL FUSIONS

AMP™ chemistry utilizes open-ended targeted amplification to identify gene fusions whether or not the partner is known.



LOW INPUT

AMP chemistry was purpose-built for library prep from low-input and degraded samples such as FFPE tissue.



EXPRESSION

Molecular barcoded fragments enable accurate RNA abundance calculations.

SPLICE VARIANTS & ISOFORMS OF INTEREST

Detect cancer-associated events such as METex14 skipping, EGFRvIII or kinase domain duplications.




FUSIONS



SNVs & InDELS



SPLICING



EXPRESSION

QUIVER[®] FUSION DATABASE

Powerful fusion analysis combined with a curated database of relevant known translocations.



CUSTOMIZATION

Create from scratch or modify any panel to keep up with the pace of discovery.

Sensitive fusion detection without prior knowledge of fusion partners.

Standard NGS assays detect a limited number of NTRK1/2/3 fusion partners

Archer AMP™ chemistry can detect all NTRK1/2/3 fusion partners



Wheels show known NTRK1/2/3 fusion partners

*Data on file

NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer recommend RNA-based NGS to maximize fusion detection

1 “It is recommended that testing be performed via a broad, panel-based approach, most typically performed by NGS. For patients who, in broad panel testing don't have identifiable driver oncogenes, consider RNA-based NGS if not already performed, to maximize detection of fusion events.”[†]

2 “Various methodologies can be used to detect NTRK gene fusions, including: FISH, IHC, PCR, and NGS; false negatives may occur. IHC methods are complicated by baseline expression in some tissues. FISH testing may require at least 3 probe sets for full analysis. NGS testing can detect a broad range of alterations. DNA-based NGS may under-detect NTRK1 and NTRK3 fusions.”[†]

[†]The NCCN Guidelines for NSCLC provide recommendations for individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays.

[†]Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.2.2020. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed January 27, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.



ARCHER™
Analysis 
Unlimited

Archer Analysis provides deep analytical metrics in an easy to interpret interface.



Powerful
Bioinformatics



Ultimate
Adaptability



User-Friendly
Analysis



Secure
Platform

Available for *local* or private *cloud-based* installation

ANALYZE

- Simple, Intuitive Web-Based Interface
- Integrate LIMS Data
- Automate Sample Processing
- Customize Outputs

INTERPRET

- Comprehensive Sample and Fusion QC Metrics
- Visualize Fusions, Variants, Expression
- Dynamic Post-Processing Filtering Sets
- Third-Party or Locally Curated Annotations

REPORT

- Assignment and Tracking
- Customize PDF Reports
- Automate With Third-Party Software
- Easy to Interpret Reporting